Roche’s Avastin plus chemotherapy receives positive recommendation from CHMP for EU approval in advanced cervical cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of Avastin® (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Chemotherapy | Pharmaceuticals